This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

17 Oct 2013

Activaero Further Strengthens Cystic Fibrosis Competence Through New Research Collaboration with Stanford University

Activaero GmbH, a therapeutic area specialist for respiratory diseases focusing on novel, pharmacoeconomically meaningful treatment solutions for severe lung diseases, has entered into a research collaboration with Stanford University, a world-leading institution for research and education. The parties will jointly evaluate the potential of Activaero's flow and volume regulated FAVORITE inhalation approach in the treatment of Cystic Fibrosis patients with hypertonic saline compared with treatment with standard nebulizers.

The proof-of-concept study will specifically assess for changes in small airway pulmonary function parameters after a therapy session of 7% hypertonic saline delivered by a standard Pari-LC Jet nebulizer and FAVORITE inhalation as well as differences in sputum production with each inhalational device. In addition, differences in the tolerability of 7% hypertonic saline delivered with each inhalational device will be monitored.

FAVORITE inhalation allows for optimum drug distribution across the entire lung importantly including the small airways. This most distal region of the lung is typically not accessible with standard nebulizer systems due to the obstructions caused by scarred tissue and mucus in the lungs of Cystic Fibrosis patients.

"Besides our internal research focus on severe asthma, Activaero has always been fully dedicated to improving the quality of life of patients suffering from Cystic Fibrosis with its inhalation approach. As there are a variety of therapeutic approaches to manage the symptoms and consequences of the disease, we are investigating a whole portfolio of solutions together with high caliber partners such as Stanford University," commented Gerhard Scheuch, Founder and Chief Executive Officer of Activaero GmbH. "Currently, hypertonic saline treatments are performed with conventional nebulizers delivering only a small fraction of the solution to the small airways. A higher dose in the periphery of the lungs may help improving lung function and sputum production." 

Related News